NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
08/26/2024
Back to search
Official data from USPTO
REPLIMUNE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
REPLIMUNE
ST13
US500000087322937Class
5, 42
Filing
87322937
Registration
5353768
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
08/26/2024
Trademark type
Word
Nice classes
5, 42
Filing date
02/02/2017
Registration date
12/12/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/26/2024
Last transaction
08/26/2024
Responsible office
United States Patent and Trademark Office
Status code
705
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
Oxfordshire, GB
Examiner
JOHNSON, CLINTON
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Replimune Limited
Representatives
Melanie Howard LOEB & LOEB LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biological preparations in the nature of viruses for the treatment of cancertumorsinfectiousoncologicalautoimmuneimmune system diseases and disorders; viruses for the treatment of cancer and tumors; viruses for inducing immune response for the treatment of cancertumorsinfectiousoncologicalautoimmuneimmune system diseases and disorders; pharmaceutical preparations and pharmaceutical substances for the treatment of infectiousoncologicalautoimmuneimmune system diseases and disorders; pharmaceutical preparations and pharmaceutical substances used for the prevention and treatment of cancer and tumors; pharmaceuticalsanti-infectives for the treatment of cancertumorsinfectiousoncologicalautoimmuneimmune system diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceuticals for inducing immune response for the treatment of cancer and tumors; vaccines; immunotherapy productspharmaceuticals for the treatment of cancertumorsinfectiousoncologicalautoimmuneimmune system diseases and disorders; gene therapy productstherapeutics for the treatment of cancertumorsinfectiousoncologicalautoimmuneimmune system diseases and disorders
Class 42
Pharmaceutical drug research and development services; research and development of vaccines and medicines; informationadvisory and consultancy services regarding research and development in the fields of pharmaceuticalsvaccines and medicines
Publications
History of USPTO decisions and trademark events.
29 publications found
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
08/26/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/12/2024
E815
TEAS SECTION 8 & 15 RECEIVED
12/06/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/12/2022
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
09/04/2020
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
09/20/2018
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
09/10/2018
PRAM
POST REGISTRATION ACTION MAILED - SEC. 7
04/11/2018
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/28/2018
ES7R
TEAS SECTION 7 REQUEST RECEIVED
02/20/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
12/12/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/26/2017
PUBO
PUBLISHED FOR OPPOSITION
09/26/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/06/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/19/2017
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
08/18/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/14/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/14/2017
ALIE
ASSIGNED TO LIE
08/14/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/04/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/19/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/11/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/04/2017
GNRT
NON-FINAL ACTION E-MAILED
05/04/2017
CNRT
NON-FINAL ACTION WRITTEN
05/04/2017
DOCK
ASSIGNED TO EXAMINER
04/27/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/07/2017
NWAP
NEW APPLICATION ENTERED
02/06/2017
Continuous trademark protection
Get notified about every new filing that threatens REPLIMUNE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.